WT1 mutations and single nucleotide polymorphism rs16754 analysis of patients with pediatric acute myeloid leukemia in a Chinese population

References

• Becker H, Marcucci G, Maharry K, . Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:788–792.
   PubMed Web of Science ®Google Scholar
• Ho PA, Zeng R, Alonzo TA, . Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2010; 116:702–710.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, . Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733–3739.
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Sagot C, Boissel N, . Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717–2723.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Stolze I, . CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004;22:624–633.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, . Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326–4335.
   PubMed Web of Science ®Google Scholar
• Call KM, Glaser T, Ito CY, . Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 1990;60:509–520.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Menssen HD, Gaiger A, . Wilms’ tumour gene 1 (WT1) in human neoplasia. Leukemia 2005;19:1318–1323.
   PubMed Web of Science ®Google Scholar
• Ellisen LW, Carlesso N, Cheng T, . The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 2001;20:1897–1909.
   PubMed Web of Science ®Google Scholar
• Damm F, Heuser M, Morgan M, . Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010;28:578–585.
   PubMed Web of Science ®Google Scholar
• Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, . Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009;113:5951–5960.
   PubMed Web of Science ®Google Scholar
• Hou HA, Huang TC, Lin LI, . WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010;115:5222–5231.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Krauter J, . Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909–1918.
   PubMed Web of Science ®Google Scholar
• Lauhakirti D, Sritana N, Boonthimat C, . WT1 mutations and polymorphisms in Southeast Asian acute myeloid leukemia. Exp Mol Pathol 2011;91:682–686.
   PubMed Web of Science ®Google Scholar
• Choi Y, Lee JH, Hur EH, . Single nucleotide polymorphism of Wilms’ tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Ann Hematol 2012;91:671–677.
   PubMed Web of Science ®Google Scholar
• Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol 2004;31: 185–197.
   PubMed Web of Science ®Google Scholar
• Juhl-Christensen C, Ommen HB, Aggerholm A, . Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatr Blood Cancer 2012;58:525–531.
   PubMed Web of Science ®Google Scholar
• Altshuler DM, Gibbs RA, Peltonen L, . Integrating common and rare genetic variation in diverse human populations. Nature 2010;467:52–58.
   PubMed Web of Science ®Google Scholar
• Becker H, Maharry K, Radmacher MD, . Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica 2011;96: 1488–1495.
   PubMed Web of Science ®Google Scholar
• Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, . No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. J Clin Oncol 2010;28: e523–e526; author reply e527–e528.
   Web of Science ®Google Scholar
• Renneville A, Boissel N, Helevaut N, . Wilms’ tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. Leukemia 2011;25:1918–1921.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, . Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620–625.
   PubMed Web of Science ®Google Scholar
• Xu XJ, Tang YM, Song H, . Long-term outcome of childhood acute myeloid leukemia in a developing country: experience from a children's hospital in China. Leuk Lymphoma 2010;51:2262–2269.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Basel: Karger; 2009.
   Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.
   PubMed Web of Science ®Google Scholar
• Al-Ali HK, Heinrich MC, Lange T, . High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004;5:55–60.
   PubMedGoogle Scholar
• Paschka P, Marcucci G, Ruppert AS, . Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904–3911.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Kopecky KJ, Meshinchi S, . Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006;107:3724–3726.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Mandava S, Das BR. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol 2009;27:90–97.
   PubMed Web of Science ®Google Scholar
• Brown P, McIntyre E, Rau R, . The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007;110:979–985.
   PubMed Web of Science ®Google Scholar
• Gombart AF, Hofmann WK, Kawano S, . Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002;99:1332–1340.
   PubMed Web of Science ®Google Scholar
• Lin LI, Chen CY, Lin DT, . Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005;11:1372–1379.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Stoll R, Lee BM, Debler EW, . Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol 2007; 372:1227–1245.
   PubMed Web of Science ®Google Scholar
• King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms’ tumor gene WT1 in leukemias. Blood 1996;87: 2171–2179.
   PubMed Web of Science ®Google Scholar
• King-Underwood L, Pritchard-Jones K. Wilms’ tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998;91:2961–2968.
   PubMed Web of Science ®Google Scholar
• Renneville A, Boissel N, Zurawski V, . Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009;115:3719–3727.
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Moschny S, . Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009; 113:4505–4511.
   PubMed Web of Science ®Google Scholar
• Nakase K, Bradstock K, Sartor M, . Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia 2000;14: 163–168.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717–720.
   PubMed Web of Science ®Google Scholar
• Ho PA, Kuhn J, Gerbing RB, . WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol 2011;29:704–711.
   PubMed Web of Science ®Google Scholar
• Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, . Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007;67:9609–9612.
   PubMed Web of Science ®Google Scholar
• Mahlknecht U, Dransfeld CL, Bulut N, . SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia 2009;23:1929–1932.
   PubMed Web of Science ®Google Scholar
• Wagner K, Damm F, Gohring G, . Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356–2364.
   PubMed Web of Science ®Google Scholar
• Lapillonne H, Renneville A, Auvrignon A, . High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24: 1507–1515.
   PubMed Web of Science ®Google Scholar
• Hashii Y, Sato-Miyashita E, Matsumura R, . WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission. Leukemia 2012;26:530–532.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Letsch A, Busse A, . A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113: 6541–6548.
   PubMed Web of Science ®Google Scholar
• Noronha SA, Farrar JE, Alonzo TA, . WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;53: 1136–1139.
   PubMed Web of Science ®Google Scholar